GlobeNewswire

AroCell expands with a Regulatory Affairs Director

Share

AroCell AB (publ.) announces today that Peter Löwendahl joins the management team as senior director regulatory affairs. Peter Löwendahl will lead and develop AroCell’s regulatory strategy with focus on the US market and FDA clearance of our TK 210 ELISA.

Peter Löwendahl has almost 30 years of experience in quality and regulatory affairs and has previously been responsible for Quality and Regulatory affairs at Elekta AB and global regulatory responsibility for GE Healthcare's Life science division. In the last 3 years, he works mainly as a senior consultant and advisor for Hoff & Lowendahl AB.

“I’m very glad that we attracted Peter as responsible for AroCell’s regulatory strategy. AroCell is in an exciting phase entering into the US market and the regulatory path is an important part of this”, says Michael Brobjer, CEO at AroCell. “Peter’s long experience of setting medical devices on the US market gives me confidence that he will add knowledge and experience into the company.”

”I look forward working with AroCell and their biomarker assay. I’m impressed of what a small team can accomplish and eager to be a part of it”, says Peter Löwendahl.

For more information:
Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

This information was submitted for publication through the agency of Michael Brobjer, September 11, 2019 at 14:00.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.
For more information; www.arocell.com



Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Mandalay Resources Corporation Announces Financial Results for the Second Quarter of 202012.8.2020 23:45:02 CESTPress release

TORONTO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) today announced its financial results for the quarter ended June 30, 2020. The Company’s unaudited condensed and consolidated interim financial results for the quarter ended June 30, 2020, together with its Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under the Company’s profile on www.sedar.com and on the Company’s website at www.mandalayresources.com. All currency references in this press release are in U.S. dollars except as otherwise indicated. For the second quarter of 2020, the Company generated revenue of $42.3 million, adjusted EBITDA of $21.3 million, and adjusted net income of $7.6 million, or $0.08 income per share. Commenting on the results, Dominic Duffy, President and CEO of Mandalay, noted, “Mandalay’s strong second quarter financial performance was driven by another all-time record in quarterly ad

Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease12.8.2020 22:01:00 CESTPress release

-- Companies to jointly validate novel drug targets -- -- Scipher eligible for upfront, opt-in and milestone payments -- -- Galapagos to progress selected targets into drug discovery -- Mechelen, Belgium and Boston, USA; 12 August 2020 - Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD). Scipher combines its proprietary Network Medicine Platform with molecular patient data and AI-based methods to identify novel targets and pathways in autoimmune diseases, including IBD. Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development. Under the terms of the agreement, Scipher is eligible to rec

AND International Publishers NV (ticker: AND.AS) publishes its half year results and trading update12.8.2020 18:05:00 CESTPress release

Capelle aan den IJssel, the Netherlands, 12 August 2020: AND International Publishers NV (ticker: AND.AS) is pleased to share today its half year results and trading update TRADING UPDATE AND HALF YEAR 2020 RESULTS AND grows topline by 22% and reduces net loss by 19% in Covid-19 impacted economic environment. Covid-19 and the related measures taken to prevent the spread of the Corona virus have proved to be a significant challenge for the global economy. The AND team and our underlying business have shown resilience: revenue has increased by 22% compared to the same period in 2019. This is mainly due to our success in winning and delivering new service projects, and moderately growing our existing recurring business. The direct impact of the lockdown was felt most in the data sales segment, where it was difficult to connect with key decision makers and win new customers. OPERATIONAL HIGHLIGHTS AND STRATEGY UPDATE The year began with a good sales pipeline, but the anti-pandemic measures

Volta Finance Limited - Director/PDMR Shareholding12.8.2020 18:03:45 CESTPress release

12 August 2020 VOLTA FINANCE LIMITED (VTA / VTAS) Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons On 12 August 2020, Mr Paul Meader, Director and Chairman of the Board of the Company, transferred 4,495 shares in the Company to his wife, Sarah Kingwell. Following this transaction the total interests in the Company of Mr Meader (and his Closely Associated Persons) remain unchanged at 40,598 shares, representing 0.11% of the issued shares in the Company. The below notification, made in accordance with the requirements of article 19.3 of the EU Market Abuse Regulation, gives further details: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Paul MeaderSarah Kingwell 2 Reason for the notification a) Position/status Director and Chairman PCA b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auct

Volta Finance Limited : Net Asset Value as at 31 July 202012.8.2020 18:00:00 CESTPress release

Volta Finance Limited (VTA / VTAS) – July 2020 monthly report NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 12 August 2020 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for July. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY In July the monthly performance, after considering the 11 cents per share dividend paid 29th of July, is negative at -1.2%. Despite a flat performance at the asset class level, USD weakness had a negative impact as USD depreciated against EUR by 4.6% during the month while, after adjusting for hedging, Volta has a USD exposure close to 45%. The monthly asset class performances** were, in local currency: -0.3% for Bank Balance Sheet transactions, +1.1% for CLO Equity tranches; -0.5% for CLO Debt; +5.9% for Cash Corporate Credit deals (this